【Founders: What's Your Why?】
Occasionally, when meeting with founders, we're often asked about what exactly we look for when investing in startups.
Is it a killer product? A scalable business model? User stickiness? Track record of success? Large addressable market?
Those are all certainly core facets of an attractive deal, albeit present across varying degrees. But one of the most important considerations that we spend a great deal of time trying to understand is the founder's Heart (among our core framework of Heart, Head, Hand), and more specifically the "why."
If COVID-19 is any indication, unpredictability and volatility can completely derail a startup at any given time. Although an outlier event in many respects, the outbreak is still but a microcosm compared to all the trials and tribulations that are bound to arise along a founder's journey.
If it's not a worldwide pandemic, then it's a co-founder abruptly quitting, a term sheet falling through, an inhibiting regulation, a competitor poaching top talent, a Google or Amazon entering your space, a loss of a key account, or perhaps a failed relationship or marriage--essentially a myriad of constant challenges that seem to do nothing but put your mental resolve and willpower to the test.
In tumultuous times, it's then important to always go back to your underlying reason for starting the company. As famously preached by the German philosopher Frederick Nietzsche, "He who has a why to live can bear almost any how."
For some, it's to scratch their own itch or solve their own problem. For others, it's to create a better world for their offspring and impact loved ones and those around them.
Regardless, the "why" is what will give meaning to founders' efforts in the face of adversity, allowing them to ride out rough patches and generate the conviction to see things through to the end.
Global restrictions on movement and trade have created unprecedented economic and operational challenges for companies across the value chain. Founders, use this time as an opportunity to revisit your why, clarify and affirm your reasons for starting a business. In this way, you'll have a stronger and more fortified foundation to capitalize on the upswing when things start to recover.
-Jun Wakabayashi
Analyst, AppWorks
同時也有10000部Youtube影片,追蹤數超過2,910的網紅コバにゃんチャンネル,也在其Youtube影片中提到,...
「indication meaning」的推薦目錄:
indication meaning 在 台灣光鹽生物科技學苑 Facebook 的精選貼文
<生醫新聞>Cyclacel臨床三期的急性骨髓性白血病藥物在關鍵研究中失敗
#AcuteMyeloidLeukemia #FailedTrials #ClinicalResearch #Cyclacel #Decitabine #Sapacitabine #FDA
Cyclacel Pharmaceuticals has been taught the meaning of futility. Two years after an independent data monitoring board told Cyclacel its phase 3 acute myeloid leukemia (AML) trial was destined to fail, the ever-optimistic biotech has reported its drug sapacitabine was unable to better the active control in terms of overall survival.
The top-line data confirm an outcome that looked likely from the minute independent advisers told Cyclacel the study had failed an interim futility review in December 2014. By then, the phase 3 trial had chalked up 247 of the 424 patient deaths needed to trigger the end of the study. But, with the review finding no safety issues that would force Cyclacel to shutter the study, the NJ-based biotech pushed ahead regardless.
A little more than two years later, Cyclacel has learnt sapacitabine is no better at improving overall survival in elderly patients with AML than decitabine, an Otsuka drug FDA rejected in the indication in 2012 on the basis that it also failed to outperform the control arm in its own study. Decitabine, sold under the name Dacogen as a treatment for myelodysplastic syndromes, is used off-label in elderly AML patients because of the dearth of options in this population.
When combined with the performance of sapacitabine against some secondary endpoints, the lack of options for elderly patients with AML who cannot or will not undergo chemotherapy has given Cyclacel encouragement to continue seeking a way forward for the drug.
“We plan to discuss the data with European and U.S. regulatory authorities once subgroup analyses are completed over the next few months and will report our further plans as they develop,” CEO Spiro Rombotis said in a statement.
Rombotis and the chair of the phase 3, MD Anderson’s Hagop Kantarjian M.D., picked out the data on complete remission and safety as cause for optimism. Kantarjian, a critic of FDA’s decision to reject decitabine in AML, called the improved rate of complete remission “remarkable.” Cyclacel said the safety of the two arms was similar.
While Rombotis and Kantarjian see the data as suggesting it is still too early to write off sapacitabine, investors were less optimistic. Cyclacel dropped 30% in premarket trading, adding further woes to a stock that is down 99% on the highs it hit a decade ago. The company’s market cap prior to news of the latest setback stood at $24 million.
資料來源:http://www.fiercebiotech.com/…/cyclacel-aml-drug-fails-phas…
indication meaning 在 Indication Meaning - YouTube 的必吃
... <看更多>